Investors

Investors 2017-08-18T12:57:17+00:00

Dimerix is discovering and developing important new drug therapies for major unmet medical needs identified using our proprietary cell-based drug discovery platform.

At the same time, our transformative drug discovery technology, known as Receptor-HIT, provides Dimerix with ongoing revenues from global industry partners seeking to improve their own programs.

Our vision is to positively improve human health through the creation of new treatments for major unmet medical needs.

Latest ASX Announcements

DMX-200 data to be presented at ASN Kidney Week 2017

Dimerix Limited is pleased to announce that a detailed analysis of the data from the DMX-200 Phase 2a clinical trial in Chronic Kidney Disease will be announced to the ASX coincident with its feature as [...]

Dimerix Bioshares Presentation

Dimerix CEO Kathy Harrison presented our work on DMX-200 at the 2017 Bioshares Biotech Summit in Queenstown, New Zealand last week. You can download her presentation here.

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

Conference Call Recording: DMX-200 Phase 2a Trial Results

A recording of the public DMX-200 Phase 2a trial presentation and Q&A session is available below.   This presentation was held on 13 July 2017. The corresponding presentation is available here.  

Read More

Media Coverage

Dimerix in the news following positive Phase 2a trial results in Chronic Kidney Disease

As you may know, Dimerix was pleased to release positive results for our DMX-200 Phase 2a trial in Chronic Kidney Disease (CKD) on 12 July 2017. You can see that announcement here. Following the data [...]

Video: NDF Research interview on Phase 2a results

In the interview, Kathy Harrison and Associate Professor David Packham, a Principal Investigator in the DMX-200 Phase 2a study and Director of Melbourne Renal Research Group, discusses Dimerix’s Phase 2a trial result of DMX-200 with [...]

NDF Research: An update report on Dimerix

View the update analyst report on their website.

The Australian: “Trial results ‘exciting’ for biotech Dimerix”

Dimerix CEO Kathy Harrison interviewed by The Australian Read the article on their website.

Read More

Stock Quote

View stock price: ASX Stock Price

Email Alert

subscribe to news updates